We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+39.69%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.16B
AUM Growth
+$655M
Cap. Flow
-$8.33M
Cap. Flow %
-0.26%
Top 10 Hldgs %
29.57%
Holding
149
New
12
Increased
35
Reduced
32
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$68M
2
HUM icon
Humana
HUM
+$58.7M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$21.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$21M
5
APRE icon
Aprea Therapeutics
APRE
+$19.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$49M
2
ABBV icon
AbbVie
ABBV
+$39.8M
3
SYK icon
Stryker
SYK
+$38.7M
4
MDCO
Medicines Co
MDCO
+$32.8M
5
CI icon
Cigna
CI
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 90.33%
2 Consumer Staples 0.66%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
126
Adicet Bio
ACET
$74.7M
– –
-3,571
Closed -$3.54M
ELV icon
127
Elevance Health
ELV
$85.5B
– –
-27,000
Closed -$6.48M
MOH icon
128
Molina Healthcare
MOH
$10.3B
– –
-214,500
Closed -$23.5M
NVAX icon
129
Novavax
NVAX
$1.31B
– –
-162,500
Closed -$816K
PBYI icon
130
Puma Biotechnology
PBYI
$454M
– –
-587,400
Closed -$6.32M
SAGE
131
DELISTED
Sage Therapeutics
SAGE
– –
-92,500
Closed -$13M
SYK icon
132
Stryker
SYK
$130B
– –
-179,000
Closed -$38.7M
KA
133
DELISTED
Kineta, Inc. Common Stock
KA
– –
-2,857
Closed -$338K
CBAY
134
DELISTED
Cymabay Therapeutics
CBAY
– –
-900,000
Closed -$4.61M
CLVS
135
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-256,000
Closed -$1.01M
KLDO
136
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
– –
-100,050
Closed -$753K
GWPH
137
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-95,000
Closed -$10.9M
CORV
138
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
– –
-1,200,000
Closed -$2.4M
ONCE
139
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-505,371
Closed -$49M
ALDR
140
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-1,300,000
Closed -$24.5M
CELG
141
DELISTED
Celgene Corp
CELG
– –
-185,150
Closed -$18.4M
LJPC
142
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-425,000
Closed -$3.74M
2 3 4 5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rock Springs Capital Management held 149 positions worth $3.16B, up 26% from $2.51B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2019 filing shows 12 new, 35 increased, 32 reduced and 19 closed positions. Its largest new stake was Humana: 185,000 shares worth $67.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2019 buy was Humana: 185,000 shares worth $67.8M.
  • Rock Springs Capital Management added most to Johnson & Johnson in Q4 2019, an estimated $68M increase.
  • Rock Springs Capital Management's biggest Q4 2019 reduction was Medicines Co, cutting an estimated $32.8M.
  • Rock Springs Capital Management fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $3.16B portfolio in Q4 2019.
  • Rock Springs Capital Management opened 12 new positions and closed 19 in Q4 2019.
  • Rock Springs Capital Management's portfolio value rose 26% quarter-over-quarter to $3.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.